Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program — Stella

Recruiting

Back to Hereditary Transthyretin-mediated (hATTR) Amyloidosis trials

Trial locations(7 sites)

United States

Clinical Trial Site, Iowa City, Iowa

France

Clinical Trial Site, Nantes

Germany

Clinical Trial Site, Münster

Italy

Clinical Trial Site, Pavia

Netherlands

Clinical Trial Site, Groningen

Key details

Sponsor

Alnylam Pharmaceuticals

Enrollment target

~10 participants

Started

August 2020

Primary completion

October 2030

Sex

Female only

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov